The Relationship between Age-Related Macular Degeneration and Cardiovascular Disease: A Meta-Analysis

Jungmin LEE¹, Heuy Sun SUH², *In Cheol HWANG²

1. Department of Cognitive Science, University of California, Berkeley, CA, USA
2. Department of Family Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, South Korea

*Corresponding Author: Email: spfe0211@gmail.com

(Received 15 Aug 2020; accepted 16 Oct 2020)

Abstract
Background: Age-related macular degeneration (AMD) and cardiovascular disease (CVD) share pathogenic mechanisms, and their lead-lag relationship remains unclear. We performed a meta-analysis of data from longitudinal studies to evaluate the interactive association between age-related macular degeneration (AMD) and cardiovascular disease (CVD).

Methods: A literature search was performed in PubMed, Embase, and Cochrane Library up to Feb 2019. Estimates were pooled by study quality and type of AMD and CVD. Publication bias was assessed by Begg’s test.

Results: We identified nine studies for the risk of AMD in CVD and ten studies for the risk of CVD in AMD. Overall, evidence for the risk of CVD in AMD patients was most robust. Both early and late AMD preceded CVD, but more solid significance existed in late AMD. Among the types of CVD, stroke was more tightly associated with AMD than coronary heart disease. Publication bias was not significant in either direction.

Conclusion: AMD is a risk factor for CVD, which is primarily driven by the increased risk of stroke in patients with late AMD. Moreover, these results suggested that AMD treatment and screening for CVD in AMD patients may have unexplored clinical benefits.

Keywords: Age-related macular degeneration; Cardiovascular disease; Meta-analysis; Stroke

Introduction

Age-related macular degeneration (AMD) is a major public concern and a leading cause of blindness (1). Despite advancements in medical and surgical intervention, AMD is considered an epidemic, with the global prevalence predicted to rise to 288 million by 2040 (2). The blindness resulting from AMD causes many health problems, including falls (3), fractures (4), and loss of independence (5, 6). The economic burden of AMD is also substantial: analyses of US medical claims data have estimated the annual cost of AMD to be $575–733 million (7). AMD is a multifactorial disease (8). Risk factors for AMD include cigarette smoking, lack of physical exercise, nutritional factors, genetic markers, and cardiovascular risk factors (1). Nutritional and behavioral modifications can reduce incident AMD and progression to advanced forms, and genetic counseling may aid in the early detection of AMD. Although the current evidence suggested that there are multiple similarities between the pathogenic mechanisms of AMD and cardiovascular disease (CVD) (e.g., advancing age, smoking, obesity, C-reactive protein, apo-lipoprotein E.
gene, and complement factor H), the relationship between AMD and CVD has not been clearly elucidated (9, 10). Of note, it remains unclear which condition follows or precedes the other, and the implications of this chronological order are likely to differ considerably.

To date, associations between AMD and CVD have been investigated by many researchers, but a consensus has yet to be reached. Many studies examining this relationship have been cross-sectional. Prior meta-analyses of longitudinal studies reported that AMD is predictive of a small (11) or absent increase (12) in risk of future CVD. Other systematic reviews focused on the specific types of AMD (13) or CVD (14). Theses analyses lacked some relevant papers and included studies with a specific disease setting (15), mortality (12), or multiple papers that were published using the same database (16, 17).

The purpose of this study was to conduct a systematic review and meta-analysis of longitudinal studies to investigate the chronological sequence between AMD and CVD by examining their associations in both directions.

Methods

We followed the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) guidelines to conduct our review and analysis of associations between AMD and CVD (18). Ethical approval was waived, as this study used data extracted from published literature.

Literature Search and Selection

We performed a systematic literature search of all studies published with PubMed, Embase, and the Cochrane Library from inception to Feb 01, 2019, without language restrictions. Search terms were related to AMD and CVD (Appendix 1). Citations were first scanned at the title and abstract level. The bibliographies of the full text articles were examined for congruent but uncaptured references.

Literatures with a cross-sectional nature in which the order of occurrence of AMD and CVD was unknown were excluded a priori to ensure causal inference. The inclusion criteria were as follows: 1) a population-based cohort study published as original research; 2) the baseline study group was the general population (i.e., excluding studies of disease-specific populations, such as diabetes patients); and 3) relative risks, odds ratios, or hazard ratios (HRs) with 95% confidence intervals (CIs) were provided. If there was more than one study with an overlapping cohort, we selected the latest or most complete study. One of primary outcomes was overt CVD, not subclinical CVD or CV risk factors. When possible, we limited our search to ischemic stroke, because hemorrhagic stroke is relatively rare and has different biological mechanisms than atherosclerosis (16).

The following information was extracted from each of qualified study: 1) the first author's name; 2) publication year; 3) study design with follow-up duration; 4) study setting (number of participants); 5) types/assessment of AMD and CVD; 6) covariates adjusted; and 7) the greatest adjusted estimates with 95% CIs. In general, CVD includes coronary heart disease (CHD) and any stroke; CHD includes myocardial infarction and any angina. The AMD classification systems used in each study were recorded with the Wisconsin age-related maculopathy grading system (19) or the international classification (20). Early AMD is defined as either any soft drusen and pigmentary abnormalities or large soft drusen 125 μm or more in diameter with a large drusen area (>500 μm diameter circle) or large soft indistinct drusen in the absence of signs of late AMD. Late AMD is categorized as either pure geographic atrophy involving the foveal center (e.g., dry) or neovascular (e.g., wet; nAMD). Study selection and data collection were performed independently by two authors (JL and HSS), and inconsistencies were resolved by consensus with the third author (ICH).

Analytical Methods

Estimates reported in individual studies were pooled for analysis. The models used for analysis was dependent on heterogeneity quantified with
the $I^2$-statistic (21). Specifically, if substantial heterogeneity ($I^2>50\%$) was observed, the random-effect model with the DerSimonian and Laird method (22) was used. Forest plots were produced to assess visually each HR and corresponding 95% CI across studies. In addition, we conducted subgroup analyses using a minimum of three studies and stratified by specific types of AMD and/or CVD and quality of studies. The quality of the studies was assessed with the Newcastle-Ottawa Scale (NOS, 0–9). Overall, prospective studies with longer follow-up duration or consideration of conventional CV risk factors received high NOS scores (mean score=7.22; Appendix 2). Studies with ≥8 points according to the NOS were classified as high quality. Publication bias was assessed using Begg’s test. STATA version 12.1 (Stata Corp., College Station, TX, USA) was used for analyses. All reported probabilities were two-sided, and $P$ values<0.05 were considered statistically significant.

Results

Literature Search Results and Study Characteristics

An outline of the literature search conducted is depicted in Fig. 1. Of the 2,254 articles retrieved, 75 underwent abstract screening, and 26 met the eligibility criteria. After reviewing the full text of these studies, 11 articles were excluded, and four studies were added following identification by manual search. In total, 19 articles were included in the final analysis.

![Flow diagram of the identification of relevant articles](http://ijph.tums.ac.ir)

Fig. 1: Flow diagram of the identification of relevant articles
Table 1 summarizes the characteristics of the studies included in the analyses. Nine studies investigated the risk of AMD in patients with CVD, and ten studies explored the reverse association. Studies were published between 2003 and 2018 and included seven nested case-control studies and 12 prospective studies. Most studies were conducted in Western countries (n=16), and many studies reported multiple exposures and outcomes. We used data from each study in each analysis as appropriate. Non-neovascular AMD, cited in two studies (23, 24), was treated as early AMD based on the prevalence rate.

### Table 1: Characteristics of studies reporting the association between AMD and CVD

| Reference No. | Country          | Design (F/U years) | Types of AMD | CVD                      | NOS |
|---------------|------------------|--------------------|--------------|--------------------------|-----|
| (44)          | Singapore        | Prospective (6)    | Early        | All CVD                  | 7   |
| (45)          | UK               | Nested case-control (6) | All          | CHD (MI)                 | 7   |
| (46)          | USA              | Nested case-control (NR) | All          | CHD                      | 6   |
| (28)          | USA              | Prospective (10)   | Early        | MI, angina               | 8   |
|               |                  |                    | Late (neo/non-neo) | All stroke              |     |
| (47)          | Australia        | Prospective (4.9)  | Early/Late   | MI, angina               | 6   |
|               |                  |                    |              | All stroke               |     |
| (48)          | Barbados         | Prospective (9)    | Early/Late   | All CVD                  | 5   |
| (49)          | Denmark          | Prospective (14)   | Early/Late   | All CVD                  | 5   |
| (50)          | USA              | Prospective (5–6)  | Late (neo/non-neo) | MI                  | 6   |
|               | Australia        | Prospective (10)   | Early        | MI                       | 7   |
|               | Netherlands      |                    | Late (neo)   | All stroke               |     |
| (51)          | USA              | Prospective (10)   | Early        | MI                       | 7   |
|               |                  |                    | Late (neo)   | All stroke               |     |
| (16)          | Taiwan           | Nested case-control (4.7) | Neo          | MI                       | 8   |
|               |                  |                    |              | All stroke (ischemic)    |     |
| (17)          | USA              | Prospective (13)   | All (early)  | All stroke (ischemic)    | 9   |
| (52)          | USA              | Prospective (5.4)  | All (early/late) | CHD                  | 8   |
| (25)          | Netherlands      | Prospective (13.6) | Neo/non-neo  | All stroke (ischemic)    | 9   |
| (53)          | Israel           | Nested case-control (11) | All          | MI                       | 7   |
| (54)          | USA              | Prospective (6–7)  | Early/Late   | CHD                      | 8   |
|               |                  |                    |              | All stroke               |     |
| (26)          | USA              | Nested case-control (3.5) | Neo          | MI                       | 7   |
|               |                  |                    |              | All stroke               |     |
| (23)          | USA              | Nested case-control (2) | All (early/neo) | All stroke (ischemic)   | 7   |
| (55)          | USA              | Prospective (8)    | Early        | CHD                      | 8   |
| (24)          | USA              | Nested case-control (2) | All (early/neo) | MI                  | 7   |

AMD, age-related macular degeneration; CVD, cardiovascular disease; F/U, follow-up; NR, not reported; neo, neovascular; CHD, coronary heart disease; MI, myocardial infarction; NOS, Newcastle-Ottawa Scale

### Quantitative Synthesis

Figure 2 shows the impact of AMD type on the risk of CVD. Patients with CVD are at risk of early AMD (HR, 1.28; 95% CI, 1.04–1.58, where-as incidental CVD occurred in patients with both early AMD (HR, 1.20; 95% CI, 1.03–1.40) and late AMD (HR, 1.20; 95% CI, 1.18–1.22) (Fig. 3).
The results of the subgroup analyses, which were stratified by AMD type and/or CVD type, are presented in Table 2. Overall, studies concerning the risk of CVD in AMD were more prominently significant, and this remained true among high-quality studies. Additionally, the associations with incident CVD demonstrated higher HRs and/or narrower 95% CIs in late AMD compared to early AMD. Interestingly, stroke occurrence was more tightly associated with AMD than CHD in both directions.
Among studies of CVD risk in nAMD (five studies of any CVD, four studies of stroke, three studies of CHD), high heterogeneity was detected ($I^2 = 96.6\%, 94.9\%, \text{and} \ 96.4\%$, respectively).

### Table 2: Subgroup analyses\textsuperscript{a} of the associations between AMD and CVD

| Variable                  | No. | Summary HR (95% CI)       | Heterogeneity (%) $I^2$, $F$ | Model |
|---------------------------|-----|---------------------------|-----------------------------|-------|
| **Risk of AMD in CVD**    |     |                           |                             |       |
| Overall                   |     |                           |                             |       |
| AMD risk in CVD (28, 47-49) | 4   | 1.23 (0.99–1.52)          | 1.4                         | Fixed |
| Early AMD risk in CVD (28, 44, 47-49) | 5   | 1.28 (1.04–1.58)          | 46.6                        | Fixed |
| Late AMD risk in CVD (28, 47-49) | 4   | 1.33 (0.85–2.07)          | 0                           | Fixed |
| Early AMD risk in MI (28, 47, 51) | 3   | 1.02 (0.75–1.40)          | 0                           | Fixed |
| Late AMD risk in MI (28, 47, 50, 51) | 4   | 0.95 (0.59–1.50)          | 0.3                         | Fixed |
| Early AMD risk in stroke (28, 47, 51) | 3   | 1.56 (1.04–2.34)          | 0                           | Fixed |
| Late AMD risk in stroke (47, 50, 51) | 3   | 1.39 (0.78–2.47)          | 0                           | Fixed |
| **Risk of CVD in AMD**    |     |                           |                             |       |
| Overall                   |     |                           |                             |       |
| Any CVD in AMD (17, 23, 24, 52-54) | 6   | 1.20 (1.18–1.22)          | 34.0                        | Fixed |
| Stroke in AMD (17, 23, 54) | 3   | 1.21 (1.19–1.24)          | 0                           | Fixed |
| Any CVD in early AMD (17, 24, 52, 54, 55) | 5   | 1.18 (1.15–1.22)          | 41.2                        | Fixed |
| Any CVD in late AMD (23-25, 52, 54) | 5   | 1.26 (1.17–1.35)          | 74.3                        | Random |
| Stroke in late AMD (23, 25, 54) | 3   | 1.31 (1.26–1.36)          | 20.0                        | Fixed |
| In high-quality studies (NOS≥8) |     |                           |                             |       |
| Any CVD in AMD (17, 52, 54) | 3   | 1.27 (1.08–1.48)          | 33.1                        | Fixed |
| Any CVD in early AMD (17, 52, 54, 55) | 4   | 1.24 (1.01–1.51)          | 50.6                        | Random |
| Any CVD in late AMD (25, 52, 54) | 3   | 1.53 (1.12–2.09)          | 0                           | Fixed |

AMD, age-related macular degeneration; CVD, cardiovascular disease; HR, hazard ratio; CI, confidence interval; NOS, Newcastle-Ottawa Scale; MI, myocardial infarction.

\textsuperscript{a}Subgroup analyses involving a minimum of three studies

Thus, a descriptive review was conducted (data not shown). Briefly, in the five studies concerning risk of any CVD, three reported a significant positive association (23-25); one reported a significant negative association (26); and one reported a nonsignificant positive association (16). All but one (26) study of the risk of stroke reported a significant positive association with nAMD (16, 23, 25). Finally, of the studies involving CHD, one reported a significant positive association (24); one reported a significant negative associa-
Begg’s test showed no evidence of significant small-study effect for the analyses in either direction ($P_{\text{bias}}=0.216$ for AMD risk in CVD, $P_{\text{bias}}=0.553$ for CVD risk in AMD). Figure 4 depicts funnel plots for publication bias.

![Funnel plots for publication bias](http://ijph.tums.ac.ir)

**Fig. 4:** Begg’s funnel plots for publication bias. HR, hazard ratio. (A) Studies on the AMD risk in CVD, (B) Studies on the CVD risk in AMD

### Discussion

Similarities between AMD and CVD at the pathophysiologic and genetic levels have been reported; however, the clinical evidence linking these conditions remains inconclusive. Thus, a comprehensive summary is necessary to characterize fully the cause-and-effect relationship between AMD and CVD. By confining our analyses to longitudinal studies, the effect of temporality was greatly reduced, providing insight into causation. The main finding of our study was that AMD is a potential risk factor of CVD. The causative direction identified in this study was supported by the evidence that progression of subclinical CVD is greater in AMD patients compared to controls (27) but not vice versa (28). It is reasonable that the ultimate ischemic events of atherosclerosis, overt CVDs, are not a direct cause of AMD.

In addition, we investigated the association of AMD and CVD according to the specific types of each condition separately. The pooled analyses were needed for the relatively low prevalence of specific disease types. For example, most prospective cohort studies lacked the power to assess the association of late AMD with CVD, let alone with CVD subtypes. Our further analysis revealed as follows: 1) late AMD is a more potent predictor for CVD than early AMD; and 2) stroke is more tightly associated with AMD than CHD.

As patients with CVD, especially stroke, were more likely to develop early AMD, we hypothesized that individuals with a strong genetic predisposition to AMD may have an earlier age of onset and may be prone to preexisting CVD due to genetic or other factors. Another explanation for the relatively weak association of CVD and AMD occurrence was a selection bias. For example, nonparticipants at baseline were more likely to be fragile due to a serious sequela of CVD or be already deceased. Thus, removing these individuals who are most likely to develop future AMD may attenuate the association. In the overt CVD cohort, additional longitudinal studies examining incident AMD (especially early type) according to secondary CVD attack would assist in...
clarifying this association. Nevertheless, the underlying cause of the association of AMD in CVD patients remains unknown. According to our results, when AMD manifests first, it may serve as a useful indicator of increased risk for future CVD events. In addition, the increasing magnitude of association with future CVD from early to late AMD is biologically plausible and implies that CV risk assessment for AMD patients may be clinically useful for early detection of underlying CVD. Additional research is warranted to understand the usefulness of CVD screening among patients with AMD. Moreover, as AMD is actively treated (i.e., anti-vascular endothelial growth factor [VEGF]) to delay progression, our results highlight additional clinical considerations for CVD prevention.

In this study, the risk of stroke in AMD patients was much higher than the risk of CHD. Both AMD and CVD are associated with atherosclerosis, inflammation, and a local up-regulation of VEGF (9). Therefore, generalized atherosclerosis is unlikely to account fully for the association of stroke occurrence with AMD. It has also been reported that pathological mechanisms of lipid deposition are similar in the vessel wall and in the eye (29). All of these are true in stroke (30), and complement activation in both stroke and AMD seems to suggest a further link (31, 32). On the other hand, higher levels of high-density lipoprotein cholesterol (HDL-C) detected in AMD patients (33) may protect more strongly against CHD compared to stroke (34).

Despite high heterogeneity, the association between nAMD and stroke observed in this study was noteworthy. Our qualitative review suggested that nAMD could predict future CVD, especially stroke (positive significance in three of four studies). In contrast to other types of AMD, a diagnosis of nAMD is unlikely to be misclassified by different doctors due to the classical clinical signs (presence of exudates, hemorrhages, or retinal detachment). Potential mechanisms underlying the risk of stroke among patients with nAMD include an imbalance in matrix metalloproteinase-9 (35), deposition of the complement membrane attack complex (36, 37), and homocysteinemia (38). Furthermore, recent epidemiologic studies supported a stronger association for hemorrhagic stroke than for ischemic stroke in patients with AMD (17), late AMD (25), and nAMD (16).

Thus, specific types of AMD, such as nAMD, may be useful clinical predictors of CVD, and especially stroke.

Our study has several limitations. First, most studies were conducted in Western societies, limiting the generalization of our results to other ethnic groups. CVD incidence and CVD-prone behaviors varied across cultures (39), and the AMD types observed in Asians differed from those observed in Caucasians (40). Second, high heterogeneity was observed in several analyses. In general, heterogeneity depends on the study design, length of follow-up, covariates, and accuracy of the definitions of exposure and outcome (41). Although most of these variables were accounted for by the NOS, ascertainment of exposure and/or outcome could not be regulated satisfactorily. The types of AMD in each study were diverse, and CVD outcomes in some studies encompassed a spectrum of conditions, from asymptomatic angina to myocardial infarction. Finally, we were unable to account for dietary factors, genetic factors, or current treatment for AMD and CVD (42). This is concerning because nAMD patients being treated with anti-VEGF agents may be at increased risk for thromboembolic events (43). Additional studies are necessary to clarify the link between AMD and CVD by accounting for the effect of such treatments.

Despite the limitations, this study has both research and clinical implications. Our meta-analysis, based on the best-available evidence from longitudinal studies, indicates that AMD carries a higher risk for the development of CVD, especially stroke. Moreover, this association is even stronger in late AMD. Based on these findings, a cross-disciplinary awareness of the link between these two conditions is warranted among ophthalmologists, optometrists, cardiologists, and family physicians. Specifically, ophthalmologists should be alerted to the risk of CVD events when treating patients with AMD, especially if the patient has underlying CV risk fac-

Available at: http://ijph.tums.ac.ir
tors. In addition to further exploration of the underlying biological processes of AMD, our findings supported the need for additional observational studies examining whether treatments that delay the progression of AMD may also prevent the development of CVD.

Ethical considerations

Ethical issues (Including plagiarism, informed consent, misconduct, data fabrication and/or falsification, double publication and/or submission, redundancy, etc.) have been completely observed by the authors.

Acknowledgements

There was no funding source to declare.

Conflict of interest

The authors declare that there is no conflict of interest.

References

1. Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY (2012). Age-related macular degeneration. Lancet, 379:1728-38.
2. Wong WL, Su X, Li X, Cheung CM, et al (2014). Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health, 2(2):e106-16.
3. Nevitt MC, Cummings SR, Kidd S, Black D (1989). Risk factors for recurrent nonsyncopal falls. A prospective study. JAMA, 261(18):2663-8.
4. Cummings SR, Nevitt MC, Browner WS, et al (1995). Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med, 332(12):767-73.
5. Wang X, Lamoureux E, Zheng Y, et al (2014). Health burden associated with visual impairment in Singapore: the Singapore epidemiology of eye disease study.
6. Chiang PP, Zheng Y, Wong TY, Lamoureux EL (2013). Vision impairment and major causes of vision loss impacts on vision-specific functioning independent of socioeconomic factors. Ophthalmology, 120(2):415-22.
7. Rein DB, Zhang P, Wirth KE, et al (2006). The economic burden of major adult visual disorders in the United States. Arch Ophthalmol, 124(12):1754-60.
8. Cheung CM, Wong TY (2014). Is age-related macular degeneration a manifestation of systemic disease? New prospects for early intervention and treatment. J Intern Med, 276(2):140-53.
9. Seddon JM (2017). Macular Degeneration Epidemiology: Nature-Nurture, Lifestyle Factors, Genetic Risk, and Gene-Environment Interactions - The Weisenfeld Award Lecture. Invest Ophthalmol Vis Sci, 58(14):6513-6528.
10. Snow KK, Seddon JM (1999). Do age-related macular degeneration and cardiovascular disease share common antecedents? Ophthalmic Epidemiol, 6(2):125-43.
11. Wu J, Uchino M, Sastry SM, Schaumberg DA (2014). Age-related macular degeneration and the incidence of cardiovascular disease: a systematic review and meta-analysis. PLoS One, 9(3):e89600.
12. Wang J, Xue Y, Thapa S, et al (2016). Relation between Age-Related Macular Degeneration and Cardiovascular Events and Mortality: A Systematic Review and Meta-Analysis. Biomed Res Int, 2016:8212063.
13. Chakravarthy U, Wong TY, Fletcher A, et al (2010). Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis. BMC Ophthalmol, 10:31.
14. Fernandez AB, Panza GA, Cramer B, et al (2015). Age-Related Macular Degeneration and Incident Stroke: A Systematic Review and Meta-Analysis. PLoS One, 10(11):e0142968.
15. Voutilainen-Kaunisto RM, Terasvirta ME, Uusitupa MI, Niskanen LK (2000). Age-related macular degeneration in newly diagnosed type 2 diabetic patients and control subjects: a 10-year follow-up on evolution, risk factors, and prognostic significance. Diabetes Care, 23(11):1672-8.
16. Lee WA, Cheng CL, Lee CH, et al (2017). Risks of newly onset hemorrhagic stroke in patients with neovascular age-related macular degeneration. *Pharmacoepidemiol Drug Saf*, 26(10):1277-1285.

17. Ikram MK, Mitchell P, Klein R, et al (2012). Age-related macular degeneration and long-term risk of stroke subtypes. *Stroke*, 43(6):1681-3.

18. Stroup DF, Berlin JA, Morton SC, et al (2000). Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. *JAMA*, 283(15):2008-12.

19. Klein R, Davis MD, Magli YL, et al (1991). The Wisconsin age-related maculopathy: grading system. *Ophthalmology*, 98(7):1128-34.

20. Bird AC, Bressler NM, Bressler SB, et al (1995). An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. *Surv Ophthalmol*, 39(5):367-74.

21. Higgins JP, Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. *Stat Med*, 21(11):1539-58.

22. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003). Measuring inconsistency in meta-analyses. *BMJ*, 327(7414):557-60.

23. Liao D, Mo J, Duan Y, et al (2008). Is age-related macular degeneration associated with stroke among elderly americans? *Open Ophthalmol J*, 2:37-42.

24. Duan Y, Mo J, Klein R, et al (2007). Age-related macular degeneration is associated with incident myocardial infarction among elderly Americans. *Ophthalmology*, 114(4):732-7.

25. Wieberdink RG, Ho I, Ikram MK, et al (2011). Age-related macular degeneration and the risk of stroke: the Rotterdam study. *Stroke*, 42(8):2138-42.

26. Nguyen-Khoa BA, Goehring EL Jr, Werther W, et al (2008). Hospitalized cardiovascular diseases in neovascular age-related macular degeneration. *Arch Ophthalmol*, 126(9):1280-6.

27. Fernandez AB, Ballard KD, Wong TY, et al (2018). Age-related macular degeneration and progression of coronary artery calcium: The Multi-Ethnic Study of Atherosclerosis. *PLoS One*, 13(7):e0201000.

28. Klein R, Cruickshanks KJ, Myers CE, et al (2013). The relationship of atherosclerosis to the 10-year cumulative incidence of age-related macular degeneration: The beaver dam studies. *Ophthalmology*, 120(5):1012-9.

29. Friedman E (2000). The role of the atherosclerotic process in the pathogenesis of age-related macular degeneration. *Am J Ophthalmol*, 130(5):658-63.

30. Wong TY (2010). Age-related macular degeneration: why should stroke physicians care? *Stroke*, 41(4):575-6.

31. Di Napoli M (2001). Systemic complement activation in ischemic stroke. *Stroke*, 32(6):1443-8.

32. Edwards AO, Ritter R 3rd, Abel KJ, et al (2005). Complement factor H polymorphism and age-related macular degeneration. *Science*, 308(5720):421-4.

33. Yip JJ, Khawaja AP, Chan MP, et al (2015). Cross Sectional and Longitudinal Associations between Cardiovascular Risk Factors and Age Related Macular Degeneration in the EPIC-Norfolk Eye Study. *PLoS One*, 10(7):e0132565.

34. Wang X, Dong Y, Qi X, et al (2013). Cholesterol levels and risk of hemorrhagic stroke: a systematic review and meta-analysis. *Stroke*, 44(7):1833-9.

35. Rempe RG, Hartz AMS, Bauer B (2016). Matrix metalloproteinases in the brain and blood-brain barrier: Versatile breakers and makers. *J Cereb Blood Flow Metab*, 36(9):1481-507.

36. Zeng S, Whitmore SS, Sohn EH, et al (2016). Molecular response of chorioretinal endothelial cells to complement injury: implications for macular degeneration. *J Pathol*, 238(3):446-56.

37. Yan T, Chopp M, Chen J (2015). Experimental animal models and inflammatory cellular changes in cerebral ischemic and hemorrhagic stroke. *Neurosci Bull*, 31(6):717-34.

38. Zhou F, Chen B, Chen C, et al (2015). Elevated homocysteine levels contribute to larger hematoma volume in patients with intracerebral hemorrhage. *J Stroke Cerebrovasc Dis*, 24(4):784-8.

39. Kim AS, Johnston SC (2011). Global variation in the relative burden of stroke and ischemic heart disease. *Circulation*, 124(3):314-23.

40. Wong CW, Yanagi Y, Lee WK, et al (2016).
Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians. *Prog Retin Eye Res*, 53:107-139.

41. Glasziou PP, Sanders SL (2002). Investigating causes of heterogeneity in systematic reviews. *Stat Med*, 21(11):1503-11.

42. Sobrin L, Seddon JM (2014). Nature and nurture—genes and environment—predict onset and progression of macular degeneration. *Prog Retin Eye Res*, 40:1-15.

43. Holz FG, Schmitz-Valckenberg S, Fleckenstein M (2014). Recent developments in the treatment of age-related macular degeneration. *J Clin Invest*, 124(4):1430–1438.

44. Foo VHX, Yanagi Y, Nguyen QD, et al (2018). Six-Year Incidence and Risk Factors of Age-Related Macular Degeneration in Singaporean Indians: The Singapore Indian Eye Study. *Sci Rep*, 8(1):8869.

45. Vassilev ZP, Ruigomez A, Soriano-Gabarro M, Garcia Rodriguez LA (2015). Diabetes, cardiovascular morbidity, and risk of age-related macular degeneration in a primary care population. *Invest Ophthalmol Vis Sci*, 56(3):1585-92.

46. Thomas J, Mohammad S, Charnigo R, et al (2015). Age-Related Macular Degeneration and Coronary Artery Disease in a VA Population. *South Med J*, 108(8): 502–506.

47. Tan JS, Mitchell P, Smith W, Wang JJ (2007). Cardiovascular risk factors and the long-term incidence of age-related macular degeneration: the Blue Mountains Eye Study. *Ophthalmology*, 114(6):1143-50.

48. Leske MC, Wu SY, Hennis A, et al (2006). Nine-year incidence of age-related macular degeneration in the Barbados Eye Studies. *Ophthalmology*, 113(1):29-35.

49. Buch H, Vinding T, la Cour M, et al (2005). Risk factors for age-related maculopathy in a 14-year follow-up study: the Copenhagen City Eye Study. *Acta Ophthalmol Scand*, 83(4):409-18.

50. Tomany SC, Wang JJ, Van Leeuwen R, et al (2004). Risk factors for incident age-related macular degeneration: pooled findings from 3 continents. *Ophthalmology*, 111(7):1280-7.

51. Klein R, Klein BE, Tomany SC, Cruickshanks KJ (2003). The association of cardiovascular disease with the long-term incidence of age-related maculopathy: the Beaver Dam eye study. *Ophthalmology*, 110(6):1273-80.

52. Fernandez AB, Wong TY, Klein R, et al (2012). Age-related macular degeneration and incident cardiovascular disease: the Multi-Ethnic Study of Atherosclerosis. *Ophthalmology*, 119(4):765-70.

53. Golan S, Shalev V, Goldstein M, et al (2011). The rate of myocardial infarction events among patients with age-related macular degeneration: a population-based study. *Graefe's Arch Clin Exp Ophthalmol*, 249(2):179-82.

54. Sun C, Klein R, Wong TY (2009). Age-related macular degeneration and risk of coronary heart disease and stroke: the Cardiovascular Health Study. *Ophthalmology*, 116(10):1913-9.

55. Wong TY, Tikellis G, Sun C, et al (2007). Age-related macular degeneration and risk of coronary heart disease: the Atherosclerosis Risk in Communities Study. *Ophthalmology*, 114(1):86-91.
Appendix 1
Search strategy
#1: (macular degeneration)
#2: maculopathy
#3: (retinal degeneration)
#4: #1 OR #2 OR #3
#5: cerebrovascular
#6: apoplexy
#7: (brain vascular accident)
#8: stroke
#9: cardiovascular
#10: (coronary artery disease)
#11: (coronary heart disease)
#12: (myocardial infarction)
#13: (ischemic heart disease)
#14: #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13
#15: ratio
#16: risk
#17: incidence
#18: #15 OR #16 OR #17
#19: #4 AND #14 AND #18

Appendix 2: Methodological quality of the included studies, as assessed by the Newcastle-Ottawa Scale

| Cohort studies | Representativeness of exposed cohort | Selection of non-exposed cohort | Ascertainment of exposure | Presentation of outcome at start | Control for important factor | Assessment of outcome | Enough follow-up | Adequate follow-up | Total |
|----------------|-------------------------------------|--------------------------------|---------------------------|--------------------------------|-----------------------------|----------------------|------------------|-------------------|-------|
| Foo, 2018      | 1                                   | 1                              | 0                         | 1                              | 2                           | 1                    | 0                | 1                 | 7     |
| Klein, 2013    | 1                                   | 1                              | 0                         | 1                              | 2                           | 1                    | 1                | 1                 | 8     |
| Ikram, 2012    | 1                                   | 1                              | 1                         | 1                              | 2                           | 1                    | 1                | 1                 | 9     |
| Fernandez, 2012| 1                                   | 1                              | 1                         | 1                              | 2                           | 1                    | 0                | 1                 | 8     |
| Wiebendarf, 2011| 1                                   | 1                              | 1                         | 1                              | 2                           | 1                    | 1                | 1                 | 9     |
| Sun, 2009      | 1                                   | 1                              | 1                         | 1                              | 2                           | 1                    | 0                | 1                 | 8     |
| Wong, 2007     | 1                                   | 1                              | 1                         | 1                              | 2                           | 1                    | 0                | 1                 | 8     |
| Tan, 2007      | 1                                   | 1                              | 0                         | 1                              | 1                           | 1                    | 0                | 1                 | 6     |
| Leske, 2006    | 1                                   | 1                              | 0                         | 1                              | 0                           | 1                    | 0                | 1                 | 5     |
| Buch, 2005     | 0                                   | 1                              | 0                         | 1                              | 0                           | 1                    | 1                | 1                 | 5     |
| Tomany,        | 1                                   | 1                              | 0                         | 1                              | 1                           | 1                    | 0                | 1                 | 6     |
| Year   | Author(s)            | Score | Selection Adequate definition of cases | Selection Representativeness of cases | Selection Definition of control | Comparamility Control for important factor | Ascertainment of exposure (blinding) | Same method of ascertainment | Non-response rate | Total |
|--------|----------------------|-------|----------------------------------------|--------------------------------------|----------------------------------|---------------------------------------|-----------------------------------|-------------------------------|-----------------|-------|
| 2004   | Klein, 2003          | 1     | 1                                      | 0                                    | 1                                | 1                                     | 1                                 | 1                             | 1               | 7     |
| 2003   |                      |       |                                        |                                      |                                  |                                       |                                   |                               |                 |       |
|        | Case-control         |       |                                        |                                      |                                  |                                       |                                   |                               |                 |       |
|        | Lee, 2017            | 1     | 1                                      | 1                                    | 1                                | 2                                     | 1                                 | 1                             | 0               | 8     |
|        | Vassilev, 2015       | 1     | 1                                      | 1                                    | 1                                | 1                                     | 1                                 | 1                             | 0               | 7     |
|        | Thomas, 2015         | 1     | 1                                      | 1                                    | 1                                | 0                                     | 1                                 | 1                             | 0               | 6     |
|        | Golan, 2011          | 1     | 1                                      | 1                                    | 1                                | 1                                     | 1                                 | 1                             | 0               | 7     |
|        | Nguyen-Khoa, 2008    | 1     | 1                                      | 1                                    | 1                                | 1                                     | 1                                 | 1                             | 0               | 7     |
|        | Liao, 2008           | 1     | 1                                      | 1                                    | 1                                | 1                                     | 1                                 | 1                             | 0               | 7     |
|        | Duan, 2007           | 1     | 1                                      | 1                                    | 1                                | 1                                     | 1                                 | 1                             | 0               | 7     |